Mon07222019

Robins Global News & Noticias



  • Gaming Chair Review
    Gaming Chair Review
  • Data Recovery Review
    Data Recovery Review
  • Online Video Editors
    Online Video Editors
  • Download TV Series
    Download TV Series
  • All Elite Wrestling
    All Elite Wrestling
  • Trump Pence News
    Trump Pence News
  • Weather Alerts
    Weather Alerts

RobinsPost News Network

+ Larger Font | + Smaller Font

Globe NewsWire News Distribution Service

Press Release: Forty Seven, Inc. to Present Initial Safety and Efficacy Data from Phase 1b Clinical Trial of 5F9 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome at 2019 ASCO Annual Meeting


-- Forty Seven to Host Investor Event and Webcast on June 3, 2019 --
-- Forty Seven Management to Participate in MATTER Panel, The Current and Future Wave of Immuno-Oncology Therapies, on May 30, 2019 --
MENLO PARK, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc., a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that promising initial data from its Phase 1b clinical trial evaluating 5F9 as a monotherapy and in combination with azacitidine for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) will be presented in a poster discussion session at the 2019 ASCO Annual Meeting in Chicago, Illinois, May 31-June 4, 2019. Presentation Title: The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results
Session Title: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Session Date & Time: Monday, June 3, 2019 from 4:30 p.m. – 6:00 p.m. CT (5:30 p.m. – 7:00 p.m. ET)
Abstract Number: 7009
Location: Poster Board #384, Hall A, McCormick Place
The accepted abstract is now available online on the ASCO website: https://iplanner.asco.org.Forty Seven’s Phase 1b clinical trial evaluating 5F9 as a monotherapy and in combination with azacitidine for the treatment of AML and MDS is funded in part by a research grant awarded by the California Institute for Regenerative Medicine (CIRM).Investor Event and Webcast InformationForty Seven will host an investor event on Monday, June 3, 2019 beginning at 6:30 p.m. CT (7:30 p.m. ET) in Chicago to review the initial clinical data presented at ASCO for 5F9. The event will be webcast live and can be accessed under “Events & Presentations” in the Investors section of the Forty Seven website at www.fortyseveninc.com. A replay of the webcast will be available approximately two hours after the event and will be available for ...


Posted: 2019-05-15 21:01:00

Get Full News Story On GlobeNewsWire Press Release Service


Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.


Print Friendly and PDF Share Embed


Related News Stories From The Web And More

Related Bing News

Press Release: Forty Seven, Inc. to Present Initial Safety and Efficacy Data from Phase 1b Clinical Trial of 5F9 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome at 2019 ASCO Annual Meeting | Globe NewsWire News Distribution Service | RobinsPost News Network - Newscast

MacroGenics Provides Update on Flotetuzumab Program in Acute Myeloid Leukemia

Wed, 17 Jul 2019 18:55:00 GMT

in patients with primary refractory acute myeloid leukemia (AML), a difficult-to-treat patient population. To date, MacroGenics has enrolled 50 patients at the recommended Phase 2 dose (RP2D) in the ...

Aptose Doses First CLL Patient in Phase 1 Study of CG-806 and Doses Third Cohort in Phase 1 Study of APTO-253

Tue, 16 Jul 2019 04:05:00 GMT

Initial data from the first two cohorts demonstrate MYC inhibition in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). “We are pleased to announce that the much ...

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Wed, 10 Apr 2019 18:26:00 GMT

This phase III trial studies response-based chemotherapy in treating newly diagnosed acute myeloid leukemia or myelodysplastic syndrome in younger patients with Down syndrome. Drugs used in ...

Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes

Thu, 17 Jan 2019 06:38:00 GMT

Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation ... Clinical utility of next-generation sequencing for oncogenic mutations in patients with acute myeloid leukemia ...

What is the prognosis of acute myeloid leukemia (AML) in patients with a monosomal karyotype?

Tue, 04 Dec 2018 16:00:00 GMT

[Medline]. Cortes JE, et al. A phase 2 randomized study of low dose Ara-C with or without glasdegib (PF-04449913) in untreated patients with acute myeloid leukemia or high-risk myelodysplastic ...

Related Twitter Search

A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutati… bit.ly/32CAVAP

(Fri, 19 Jul 2019 20:39:53 +0000)

A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutati… bit.ly/32CAVAP

#clinicaltrial A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 W… ift.tt/2SoC22l

(Fri, 19 Jul 2019 14:29:20 +0000)

#clinicaltrial A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 W… ift.tt/2SoC22l

PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: This phase I trial studies the side effects and best dose of PLX51107 and how well it works with azacitidine in treating patients with acute myeloid… bioportfol.io/R8j6r5

(Fri, 19 Jul 2019 10:54:07 +0000)

PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: This phase I trial studies the side effects and best dose of PLX51107 and how well it works with azacitidine in treating patients with acute myeloidbioportfol.io/R8j6r5

SEL120 in Patients With Acute Myeloid Leukemia or Highrisk Myelodysplastic Syndrome: This firstinhuman study will evaluate SEL120 a novel small molecule CDK819 inhibitor in patients with Acute Myeloid Leukemia AML or Highrisk Myelodysplastic Syndrome… bioportfol.io/R8Yvr0

(Wed, 17 Jul 2019 09:29:07 +0000)

SEL120 in Patients With Acute Myeloid Leukemia or Highrisk Myelodysplastic Syndrome: This firstinhuman study will evaluate SEL120 a novel small molecule CDK819 inhibitor in patients with Acute Myeloid Leukemia AML or Highrisk Myelodysplastic Syndrome… bioportfol.io/R8Yvr0

“Initial data from the first two cohorts demonstrate MYC inhibition in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).” Good to have confirmed-wonder if they release the data soon?

(Tue, 16 Jul 2019 11:23:35 +0000)

“Initial data from the first two cohorts demonstrate MYC inhibition in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).” Good to have confirmed-wonder if they release the data soon?

Impact of oral voriconazole during chemotherapy for acute myeloid leukemia and myelodysplastic syndrome a Japanese nationwide retrospective cohort study.: The prevention of invasive fungal infections is important in patients with acute myeloid leukemia… bioportfol.io/R8PLX7

(Sun, 14 Jul 2019 18:17:07 +0000)

Impact of oral voriconazole during chemotherapy for acute myeloid leukemia and myelodysplastic syndrome a Japanese nationwide retrospective cohort study.: The prevention of invasive fungal infections is important in patients with acute myeloid leukemiabioportfol.io/R8PLX7

Related News Story Videos From Youtube

Leukemia AML MDS Moon Shots update


Related Videos On: Leukemia AML MDS Moon Shots update


Young cancer survivor endures three transplants to beat AML


Related Videos On: Young cancer survivor endures three transplants to beat AML


Pracinostat and Acute Myeloid Leukemia - Preliminary Data is Encouraging


Related Videos On: Pracinostat and Acute Myeloid Leukemia - Preliminary Data is Encouraging


Facts about myelodysplastic syndrome


Related Videos On: Facts about myelodysplastic syndrome


Acute myeloid leukemia (AML) - a life threatening cancer


Related Videos On: Acute myeloid leukemia (AML) - a life threatening cancer






Blow Us A Whistle

Comments (Whistles) Designed By Disqus




Company Information

Official Content Providers











PRIVACY POLICY

We recommend Firefox 3 (and above), Edge, and Chrome for dynamic performance.
© 2008-2019 RobinsPost (The Bird's Eye View Company) All rights are reserved.
RobinsPost provides links to news sites based on their RSS feeds.
All trademarks, copyrights, videos, photos and logos are owned by news sources.
News stories, videos and live streams are from trusted sources:
Bing News, Google News, Faroo News, NewsApi.org and YouTube Search Results.
ROBINSPOST Is Proudly Made In America.
Where Quality, Safety and Service Comes First.